29 studies found for:    "potassium-aggravated myotonia" OR "Myotonic Disorders" OR "Myotonia Fluctuans"
Show Display Options
RSS Create an RSS feed from your search for:
"potassium-aggravated myotonia" OR "Myotonic Disorders" OR "Myotonia Fluctuans"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Lamotrigine as Treatment of Myotonia
Conditions: Dystrophia Myotonica Type 1;   Myotonia Congenita;   Paramyotonia Congenita;   Hyperkalemic Periodic Paralysis;   Potassium-Aggravated Myotonia
Interventions: Drug: Lamotrigine;   Drug: Placebo
2 Recruiting Myotonic Dystrophy Family Registry
Conditions: Myotonic Dystrophy;   Congenital Myotonic Dystrophy;   Myotonic Dystrophy 1;   Myotonic Dystrophy 2;   Dystrophia Myotonica;   Dystrophia Myotonica 1;   Dystrophia Myotonica 2;   Myotonia Dystrophica;   Myotonic Dystrophy, Congenital;   Myotonic Myopathy, Proximal;   PROMM (Proximal Myotonic Myopathy);   Proximal Myotonic Myopathy;   Steinert Disease;   Steinert Myotonic Dystrophy;   Steinert's Disease;   Myotonia Atrophica
Intervention: Other: Patient-entered data
3 Completed Characteristics of Nondystrophic Myotonias
Conditions: Nondystrophic Myotonias;   Myotonia Congenita;   Myotonic Disorders
Intervention:
4 Completed Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders
Conditions: Paralysis, Hyperkalemic Periodic;   Hypokalemic Periodic Paralysis;   Paramyotonia Congenita
Intervention: Drug: dichlorphenamide
5 Completed Mexiletine and Non Dystrophic Myotonias
Conditions: Non-dystrophic Myotonias;   Paramyotonia Congenita;   Myotonia Congenita
Interventions: Drug: Mexiletine;   Drug: placebo
6 Unknown  Cardiovascular Consequences of NIV Withdrawal in Patients With Myotonic Dystrophy
Condition: Myotonia
Intervention: Other: withdrawal of non-invasive ventilation
7 Recruiting Observational Prolonged Trial in Myotonic Dystrophy Type 1
Condition: Myotonic Dystrophy Type 1
Intervention: Behavioral: Behavioural change intervention
8 Completed Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients
Condition: Myotonic Dystrophy
Intervention: Other: Supine spirometry
9 Active, not recruiting Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive
Conditions: Myopathy;   Muscular Weakness;   Respiratory Insufficiency
Intervention: Device: Bilevel pressure ventilator
10 Recruiting Variability of Molecular Biomarkers and Clinical Measures in People With Myotonic Dystrophy Type 1
Conditions: Muscle Myopathies;   Muscular Dystrophy;   Inherited Neuromuscular Conditions
Intervention:
11 Recruiting Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1
Condition: Myotonic Dystrophy
Interventions: Drug: Mexiletine;   Drug: Placebo
12 Recruiting European Home Mechanical Ventilation Registry
Conditions: Pulmonary Disease, Chronic Obstructive;   Amyotrophic Lateral Sclerosis;   Spinal Cord Injury;   Muscular Dystrophies;   Obesity Hypoventilation Syndrome;   Kyphoscoliosis;   Congenital Central Hypoventilation Syndrome;   Duchenne Muscular Dystrophy;   Myopathies;   Myotonic Dystrophy
Intervention:
13 Completed Methylphenidate in Myotonic Dystrophy Type 1
Condition: Dystrophia Myotonica 1
Interventions: Drug: Methylphenidate;   Drug: Placebo
14 Recruiting Efficacy and Tolerance of AVAPS Mode in Myotonic Dystrophy
Condition: Myopathy
Intervention: Device: Nocturnal ventilation
15 Recruiting Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Conditions: Myotonic Dystrophy;   Muscular Dystrophy, Facioscapulohumeral;   Muscular Dystrophy
Intervention:
16 Recruiting A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1
Condition: Myotonic Dystrophy Type 1
Interventions: Drug: ISIS-DMPKRx;   Drug: Placebo
17 Unknown  Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
Condition: Myotonic Dystrophy Type 1
Interventions: Drug: rhIGF-I/rhIGFBP-3;   Drug: placebo
18 Completed Study of Muscle Wasting and Altered Metabolism in Patients With Myotonic Dystrophy
Condition: Myotonic Muscular Dystrophy
Intervention:
19 Completed
Has Results
Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)
Condition: Myotonic Dystrophy
Intervention: Drug: SomatoKine/IPLEX
20 Completed DM1 Heart Registry - DM1 Respiratory Registry
Condition: Myotonic Dystrophy
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results    Last Page
Indicates status has not been verified in more than two years